B&K Corporation Limited (華芢生物科技（青島）股份有限公司) (2396) issued a circular announcing its 2026 First Extraordinary General Meeting (EGM) to be held on February 10, 2026, at Taishan Hall in Metropark Hotel Yingkun Beijing. According to the document dated January 26, 2026, four major resolutions will be presented:
The first resolution proposes a listing bonus distribution totaling up to RMB1.75 million. The bonus targets directors, core management, and employees who contributed to the firm’s listing process. The board will authorize the Company’s Remuneration Committee to oversee the allocation.
The second resolution seeks the reappointment of Ernst & Young as the auditor for the 2025 financial year. The board, upon the recommendation of the audit committee, will determine the fee arrangement.
The third resolution covers the Company’s proposed annual business plan overview for 2026. Key initiatives include further R&D progress on the PDGF core technology pipelines, production capacity planning, and potential international expansion. The plan also calls for robust compliance, digital finance management, and comprehensive risk controls.
The fourth resolution details the annual budgeted expenses arrangement for 2026. Highlights include RMB122.0 million for core product clinical development, RMB12.3 million for PDGF pipeline indication expansion, RMB5.8 million for other pipelines such as Mes-201 and Oli-101/201, and RMB14 million designated for capital market expenses.
Shareholders recorded in the Company’s register by February 10, 2026, are entitled to vote at the EGM. The circular advises that the register of members for H shares will be closed from February 5 to February 10, 2026, inclusive, for registration and processing of share transfers.
Comments